Cancer-associated venous thrombosis in the surgical setting

Annals of Surgery

Volumn 249, Issue 3, 2009, Pages 366-375

  Behranwala, Kasim A ^a   Williamson, Robin C N ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR; COUMARIN; COUMARIN DERIVATIVE; CYTOKINE; D DIMER; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; INTERLEUKIN 1; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; PROSTACYCLIN; THROMBIN INHIBITOR; TINZAPARIN; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ADVANCED CANCER; AGE; ANTICOAGULANT THERAPY; BLEEDING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; FILTER; HIGH RISK PATIENT; HUMAN; IMMOBILIZATION; INFERIOR VENA CAVA FILTER; LABORATORY DIAGNOSIS; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MOBILIZATION; MONOTHERAPY; MORBIDITY; MORTALITY; OPERATION DURATION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SEPSIS; SURVIVAL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ARTICLE; MASS SCREENING; NEOPLASM; SURGERY;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MASS SCREENING; NEOPLASMS; SURGICAL PROCEDURES, OPERATIVE; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 63449116221     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318195c50c     Document Type: Review

References (84)

1. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:117-121.
2. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.
3. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005;16:696-701.
4. Sorensen H, Mellemkjaer L, Steffensen F, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-1173.
5. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 1999;159:445-453.
6. Trousseau A. Phlegmasia alba dolens. In: Trousseau A, ed. Clinique Medicale De L'hotel-Dieu De Paris. Paris, France: Bailliere. 1865;3:654-712.
7. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106:6-12.
8. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243:89-95.
9. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087-1097.
10. Olas B, Mielicki WP, Wachowicz B, et al. Cancer procoagulant stimulates platelet adhesion. Thromb Res. 1999;94:199-203.
11. Rickles FR, Levine M, Edwards RL. Haemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992;11:237-248.
12. Carmeliet P, Collen D. Tissue factor. Int J Biochem Cell Biol. 1998;30:661-667.
13. Garcia JGN. Molecular mechanisms of thrombin-induced human and bovine endothelial cell activation. J Lab Clin Med. 1992;120:513-519.
14. Prandoni P, Lensing AWA, Buller HR, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
15. Hallahan D, Chen AY, Teng M, et al. Drug-radiation interactions in tumour blood vessels. Oncology (Williston Park). 1999;13:71-77.
16. Nadir Y, Hoffman R, Brenner B. drug related thrombosis in haematological malignancies. Rev Clin Exp Haematol. 2004;8:E4.
17. Di Nisio, Rutjes NWS, Buller HH. Combined use of clinical pretest probability and D-dimer test in cancer patients with clinically suspected deep venous thrombosis. J Thromb Haemost. 2006;4:52-57.
18. Lee AYY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole blood D-dimer assay in patients with cancer who presented with suspected acute venous thrombosis. Ann Intern Med. 1999;131:417-423.
19. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalised ratios: a retrospective analysis. J Clin Oncol. 2000;18:3078-3083.
20. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528693 adults. Arch Intern Med. 2005;165:1782-1787.
21. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent thromboembolism. Duration of anticoagulation trial. N Engl J Med. 2000;342:1953-1958.
22. Nordstrom M, Lindbald B, Anderson H, et al. Deep venous thrombosis and occult malignancy; an epidemiological study. Br Med J. 1994;308:891-894.
23. Otten H, Prins M. Venous thromboembolism and occult malignancy. Thromb Res. 2001;102:V187-V194.
24. Iodice S, Gandini S, Löhr M, et al. Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost. 2008;6:781-788.
25. Barosis G, Marchetti M, Dazzi L, et al. Testing for occult cancer in patients with idiopathic deep vein thrombosis:a decision analysis. Thromb Haemostat. 1997;78:1319-1326.
26. DI Nisio M, Otten HM, Piccioli A, et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost. 2005; 3:2391-2396.
27. Amarigiri SV, Lees TA. Elastic Compression Stockings for Prevention of Deep Vein Thrombosis (Cochrane Review). Oxford: The Cochrane Library; 2004. Updated software 2004.
28. Ramos R, Salem BI, DePawlikowski MP, et al. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest. 1996;109:82-85.
29. Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med. 2007;147:525-533.
30. Morita S, Gebska MA, Kakkar AK, et al. High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity-implications for cancer related thromboembolism and heparin therapy. Thromb Haemost. 2001; 86:616-622.
31. Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemostat. 1989;61:25-29.
32. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S-175S.
33. Borly L, Wille-Jørgensen P, Rasmussen MS. Systematic review of thrombopro-phylaxis in colorectal surgery-an update. Colorectal Dis. 2005;7:122-127.
34. Wille-Jorgensen P, Thorup J, Fischer A, et al. Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: a randomised trial. Br J Surg. 1985;72: 579-581.
35. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88:913-930.
36. ENOXACAN study group. Efficacy and safety of enoxaparin versus unfrac-tionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double blind randomised multicentre trial with venographic assessment. Br J Surg. 1997;84:1099-1103.
37. Von Templehoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomised double blind trial. Int J Oncol. 2000;16:815-824.
38. Galster H, Kolb G, Kohsytorz A, et al. The pre-, peri-and postsurgical activation of coagulation and the thromboembolic risk for different groups. Thromb Res. 2000;100:381-388.
39. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, et al; FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomised open-label study. J Thromb Haemost. 2006;4:2384-2390.
40. Bergqvist D, Burmark U, Flordal P, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 IU in 2070 patients. Br J Surg. 1995;82:496-501.
41. Bergqvist D, Agnelli G, Cohen A, et al. ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-980.
42. Agnelli G, Bergqvist D, Cohen AT, et al; PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005;92:1212-1220.
43. Turpie AG, Bauer KA, Caprini JA, et al; Apollo Investigators. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost. 2007;5:1854-1861.
44. Kakkar AK, Haas S, Wolf H, et al. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005;94:867-871.
45. Deheinzelin D, Braga AL, Martins LC, et al; Trombo Risc Investigators. Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil. J Thromb Haemost. 2006;4:1266-1270.
46. Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371: 387-394.
47. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence based review. Cancer. 2000;9:640-646.
48. Iorio A, Agnelli G. Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med. 2000;160:2327-2332.
49. Oates-Whitehead RM, D'Agnelo A, Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev. 2003;4:CD003679.
50. Levine M, Hirsh J, Gent M, et al. Double blind randomised trial of a very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-889.
51. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboem-bolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S-453S.
52. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low molecular weight heparin with unfractionated heparin in the treatment of venous thromboembolism; examining some unanswered questions regarding location of treatment, product type and dosing frequency. Arch Intern Med. 2000;160:181-188.
53. Van Dogen CJJ, Van den Belt AGM, Prins MH, et al. Fixed dose subcutaneous low molecular weight heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;4:CD001100.
54. Decousus H, Leizorovicz A, Parent F, et al; prevention du Risque d'Embolic Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med. 1998;338:409-415.
55. Buller HR, Agnelli G, Hull HD, et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:401-428.
56. Young T, Tang H, Aukes J, et al. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev. 2007;4:CD006212.
57. Kinney TB. Update on inferior vena caval filters. J Vasc Interv Radiol. 2003;14:425-440.
58. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulation treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
59. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Treatment. Lancet. 1996;348:423-428.
60. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163:901-908.
61. Kearon C, Hirsh J. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163:2532-2533.
62. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembo-lism in patients with cancer: a randomised controlled study. Arch Intern Med. 2002;162:1729-1735.
63. Iorio A, Guercini F, Pini M. Low molecular weight heparin for the long term treatment of symptomatic venous thromboembolism: meta analysis of the randomised comparisons with oral anticoagulants. J Thromb Haemost. 2003; 1:1906-1913.
64. Lee AY, Levine MN, Baker RI, et al. Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
65. Hull RD, Pineo GF, Brant RF, et al; LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007;120:72-82.
66. Vander Heijden JF, Hutten BA, Buller HA, et al. Vitamin K antagonists or low molecular weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2002;1:CD0020001.
67. O'Shaughnessy D, Miles J, Wimperis J. UK patients with deep vein thrombosis can be safely treated as out-patients. QJM. 2000;93:663-667.
68. Ageno W, Steidl L, Marchesi C, et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Hamatologica. 2002;87:286-291.
69. Hull R, Pineo GF, Mah AF, et al; for the LITE investigators. A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer. J Thromb Haemost. 2003;1:1373.
70. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active malignancy: a randomised study of enoxaparin sodium alone vs. initial enoxaparin sodium followed warfarin for a 180 day period. J Thromb Haemost. 2003;1:OC194.
71. Borsig L. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost. 2007;33:540-546.
72. Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol. 2005;2:356-363.
73. Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, p-selectin, carcinoma mucins and tumour metastasis. Proc Natl Acad Sci U S A. 2001;98:3352-3357.
74. Torngren S, Rieger A. The influence of heparin and curable resection on the survival of colorectal cancer. Acta Chir Scand. 1983;149:427-429.
75. Kohannna FH, Sweeney J, Hussey S, et al. Effect of perioperative low-dose heparin administration on the course of colon cancer. Surgery. 1983;93:433-438.
76. Zacharski LR, Henderson WG, Rickes VR. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate. Final report of Veterans Administration cooperative study #75. Cancer. 1984;53: 2046-2052.
77. Lebeau B, Chastang C, Brechot JM, et al; "Petites Cellules" group. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 1994;74:38-45.
78. Green D, Hull RD, Brant R, et al. Lower mortality in cancer patients treated with low molecular weight versus standard heparin. Lancet. 1992;339:1476.
79. Maurer LH, Hendon JE, Hollis DR, et al. Randomised trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small cell lung cancer: a Cancer and Leukaemia Group B study. J Clin Oncol. 1997; 15:3378-3387.
80. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-1948.
81. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123-2129.
82. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130-2135.
83. Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007;5:729-737.
84. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev. 2007:CD006652.